Abstract: A recombinant herpes virus showing high antitumor activity is provided. In particular, a recombinant herpes simplex virus that expresses an ICP6 gene under control of a tumor-specific promoter or tissue-specific promoter on the genome of the virus is provided.

Abstract: An object of the present invention is to provide a swelling-suppressive virus for treating a tumor. The present invention provides an oncolytic virus containing a gene encoding a vascular endothelial cell growth factor (VEGF) antagonist; and a pharmaceutical composition for treating a tumor, containing the oncolytic virus.

Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

Abstract: A recombinant herpes virus showing high antitumor activity is provided. In particular, a recombinant herpes simplex virus that expresses an ICP6 gene under control of a tumor-specific promoter or tissue-specific promoter on the genome of the virus is provided.

Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

Abstract: A recombinant herpes virus showing high antitumor activity is provided. In particular, a recombinant herpes simplex virus that expresses an ICP6 gene under control of a tumor-specific promoter or tissue-specific promoter on the genome of the virus is provided.

Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

Abstract: An object of the present invention is to provide a highly-safe recombinant herpes virus showing high antitumor activity regardless of the kind, grade of malignancy, or growth rate of tumor cells. The present invention provides a recombinant herpes simplex virus and the like constructed to express an ICP6 gene under control of a tumor-specific promoter or tissue-specific promoter on the genome of the virus.

Abstract: A promoter for differentiation of brain tumor initiating cells is provided.

Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.

Abstract: The present invention provides a pharmaceutical that safely and effectively enhances the anticancer activity of viral therapy and particularly the antitumor immunity of viral therapy. The present invention also provides a method of preventing or treating cancer that uses this drug. The anticancer activity enhancer according to the present invention contains interleukin as an effective component and is co-administered with a recombinant herpes simplex virus that selectively replicates in cancer cells.

Abstract: A method is provided for rapidly and reliably constructing recombinant herpes simplex virus (HSV) capable of expressing a target protein in cancer cells. The method for constructing recombinant HSV as claimed in the present invention comprises a first step of inserting into a herpes simplex virus (HSV) genome, a BAC plasmid, which has a loxP site and an FRT site and into which has been inserted at least one type of marker gene expression cassette between the loxP site and the FRP site, a second step of constructing a shuttle vector into which has been respectively inserted at least one type of expression cassette of a gene encoding a target protein, at least one type of marker gene, a loxP site and an FRP site, and inserting the shuttle vector into the loxP site of the HSV genome using Cre recombinase, and a third step of co-infecting a host with the HSV genome and a vector capable of expressing Flp recombinase, and excising the region between the FRT sites in the genome to produce a target recombinant HSV.

Abstract: The present invention provides a pharmaceutical that safely and effectively enhances the anticancer activity of viral therapy and particularly the antitumor immunity of viral therapy. The present invention also provides a method of preventing or treating cancer that uses this drug. The anticancer activity enhancer according to the present invention contains interleukin as an effective component and is co-administered with a recombinant herpes simplex virus that selectively replicates in cancer cells.

Abstract: A new gene therapy entails tumor treatment by introducing an expressible nucleotide sequence for a soluble costimulatory factor, thereby enhancing the response of T-cells to a tumor. In vivo expression of the soluble factor overcomes anergy or tolerance to tumor cells and activates T-cells that are infiltrating or surrounding the tumor. A pharmaceutical composition containing such a gene is effective in tumor suppression.